Source: Virtual Congress 2020 – ALERT: Asthma in adults and children
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Wechsler (Denver, United States of America), L. Ford (Bellevue, United States of America), J. Maspero (Buenos Aires, Argentina), I. Pavord (Oxford, United Kingdom), Y. Tohda (Osakasayama, Osaka, Japan), D. Langton (Frankston, Australia), C. Domingo (Sabadell, Barcelona, Spain), A. Papi (Ferrara, Italy), A. Bourdin (Montpellier, France), H. Watz (Grosshansdorf, Germany), H. Park (Suwon, Republic of Korea), K. Chapman (Toronto, Canada), X. Mao (Bridgewater, United States of America), B. Ortiz (Tarrytown, United States of America), M. Djandji (Cambridge, United States of America), U. Kapoor (Bridgewater, United States of America), F. Khokhar (Tarrytown, United States of America), L. Mannent (Chilly-Mazarin, France), M. Ruddy (Tarrytown, United States of America), E. Laws (Bridgewater, United States of America), N. Amin (Tarrytown, United States of America), M. Hardin (Cambridge, United States of America). Late Breaking Abstract - Dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE. 4613

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of dupilumab in patients with oral corticosteroid (OCS)-dependent, severe asthma with and without an allergic phenotype: phase 3 LIBERTY ASTHMA VENTURE Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021 Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Late Breaking Abstract - Sensibility and specificity of the “SLEEP CLINICAL RECORD” Protocol  in Brazilian children. Source: International Congress 2018 – New ideas about respiratory and sleep physiology in children Year: 2018 Impact of severe exacerbations on lung function in dupilumab-treated patients: LIBERTY ASTHMA QUEST Source: Virtual Congress 2021 – Pearls in immunology, outcome studies and clinical trials in asthma, alpha-1 antitrypsin deficiency and COPD Year: 2021 Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Late Breaking Abstract - IMPACT OF CONFINEMENT ON ALS PATIENTS DUE TO THE SARS-CoV-2 PANDEMIC Source: Virtual Congress 2020 – Pulmonary function and rehabilitation in non-respiratory disease Year: 2020 Late Breaking Abstract - RECEIVER trial: sustained use and improved outcomes with digitally supported COPD co-management Source: Virtual Congress 2021 – E-health for COVID-19 Year: 2021 Late Breaking Abstract - Efficacy of DPP1 inhibition with brensocatib in subgroups of patients with bronchiectasis- the WILLOW study Source: Virtual Congress 2020 – ALERT: Infection in adults and children Year: 2020 Dupilumab Efficacy in Asthma Patients With FEV1 60–80% Predicted on Medium-Dose ICS: LIBERTY ASTHMA QUEST Study Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Late Breaking Abstract - Effectiveness and safety of mepolizumab in real-world clinical practice: the REALITI-A study Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 Late Breaking Abstract - Long-term safety & durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - BENRALIZUMAB IN SEVERE ASTHMA: PRELIMINARY RESULTS FROM THE ITALIAN ANANKE STUDY Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 LATE-BREAKING ABSTRACT: ASSOCIATION OF SEVERE EXACERBATION WITH FEV1 DECLINE AND LOSS OF AIRWAY REVERSIBILITY IN ASTHMA Source: International Congress 2014 – Asthma: still a heterogeneous condition! Year: 2014 Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in corticosteroid (CS)-dependent severe asthma patients in LIBERTY ASTHMA VENTURE Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018 Late Breaking Abstract - Add-on mepolizumab for chronic rhinosinusitis with nasal polyps: SYNAPSE study Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Late Breaking Abstract - Compare outcomes between COPD patients treated with Tiotropium/Olodaterol (TIO/OLO) and other fixed-dose LAMA/LABAs Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020 Late Breaking Abstract - Real world patient-reported outcomes in asthma across six European countries: the NEWTON study Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 DOES THE BENEFIT FROM PULMONARY REHABILITATION DIFFER BETWEEN PHENOTYPES IN COPD? Source: Virtual Congress 2020 – Reviews and novel insights into pulmonary rehabilitation Year: 2020 Late Breaking Abstract - Switching from PDE5i to riociguat in patients with PAH: The REPLACE study Source: Virtual Congress 2020 – ALERT: Pneumothorax, cough, PAH, alveolar proteinosis Year: 2020